Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces

NCT07066813 · tracked via the Priya Life Science China tracker

Sponsor

Central South University

Phase

Observational

Started

2025-06-01

Last updated

2026-09-04

Condition(s) studied

Lung Cancer Associated With Cystic Airspaces

Study summary

The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:

* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?
* How do imaging features of cystic lesions correlate with their pathological characteristics?
* What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?
* Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination; 2. Patients who have undergone surgical lung resection; 3. Patients with complete preoperative chest CT imaging data; 4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor. Exclusion Criteria: 1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome); 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Patients with concurrent other malignancies; 4. Patients with missing or poor-quality preoperative chest CT imaging data.

Primary outcome measure(s)

DFS — From enrollment to the end of surgery for 5 years
Disease-Free Survival
OS — From enrollment to the end of surgery for 5 years
Overall Survival

Trial sites (1)

Facility	City	Region	Status
The Second Xiangya Hospital of Central South University	Changsha	Hunan	Recruiting

More Central South University trials in China

TIS for Improving Cognitive Impairment in Schizophrenia Recruiting

nTMS for Negative Symptom in Schizophrenia Recruiting

iTBS for Increased Appetite Induced by Antipsychotics Recruiting

Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in Schizophrenia Recruiting

tACS for Working Memory in Schizophrenia Recruiting

Other trials for the same condition

Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces Recruiting

Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07066813 on ClinicalTrials.gov ↗ ← All trials in China